status — research-use-only
KPV Legal Status, FDA 503A Category, and Compounding Access
Where access actually stands: a research peptide, not an approved drug, with its compounding eligibility under active FDA review — and individually named on a scheduled 2026 advisory-committee agenda. The facts, present-tense, cited to the FDA.
In plain English
Here is the KPV legal status in a sentence: it is a research peptide, not an FDA-approved medicine, and you cannot buy it as a drug or a supplement. The forward-leaning part — and it is genuinely live — is that the FDA has scheduled KPV for discussion. It is named on the public agenda of an FDA advisory-committee meeting set for July 23-24, 2026, where experts will consider whether it belongs on a list of substances that compounding pharmacies are allowed to use. That is a scheduled conversation, not a decision, not a reclassification, and not a change in today's status. Below, what that framework means and how legal compounded access works in general.
The current fact: a research peptide under FDA evaluation
KPV — the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH) — is a research peptide and is not an FDA-approved drug for any indication [1]. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulks list; substances not yet on that list are evaluated by the FDA through a public nomination process informed by the Pharmacy Compounding Advisory Committee (PCAC) — an external expert panel that advises the agency [1][3].
KPV is one of the bulk drug substances the FDA has scheduled for PCAC evaluation [3]. That is the precise present-tense status: being under evaluation is not the same as being on the bulks list, and it is not the same as being approved for compounding. This site does not assign KPV a numbered 503A category, because the FDA's current record places KPV on a scheduled-for-discussion agenda rather than in a published category [3].
Active FDA review: KPV on the July 2026 PCAC agenda
The momentum is real, and it is anchored to a specific, citable fact. KPV is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" — evaluated in both its free-base and acetate forms [3]. The same agenda also lists BPC-157, TB-500, and MOTs-C [3]. Access for this class of peptide is, in other words, under active FDA review and may expand in 2026.
That is where the momentum stops and the caution begins. A scheduled PCAC discussion is an evaluation step, not an outcome: it is not a listing decision, not a reclassification, and not a change in KPV's current status [3]. PCAC is advisory — the committee's discussion informs the FDA, but inclusion on a final bulks list is decided by FDA rulemaking, and no outcome of the July 2026 meeting can be assumed, stated, or dated [3]. This page reports a scheduled evaluation, nothing more.
The 503A and 503B framework, in brief
Two sections of the Federal Food, Drug, and Cosmetic Act govern compounding [1]. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection [1].
The constraint that matters for a research peptide is the ingredient rule: a compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list [1]. Substances that don't meet one of those conditions must be nominated and evaluated — which is exactly the process KPV is currently in [1][3]. Separately, the FDA's interim policy historically sorted nominated substances into categories, and on January 7, 2025 the FDA finalized a revised policy under which it no longer places newly nominated substances into those numbered categories [1]. None of that changes the core point for KPV: it is not an FDA-approved drug, and its compounding eligibility is under evaluation [1][3].
How legally compounded peptide access works
For peptides of this class, legal compounded access — where a substance is eligible at all — runs through a defined pathway [1]. A patient is first evaluated by an appropriately licensed prescriber, in person or through a compliant telehealth encounter, who determines whether a compounded preparation is clinically appropriate [1]. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription [1]. That prescription is then dispensed by a state-licensed 503A compounding pharmacy or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [1].
Telehealth functions here only as a front-end channel for the prescriber-evaluation step — a route to a licensed consultation and a valid prescription [1]. It does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation [1]. And the ingredient-eligibility caveat governs the whole pathway: a substance the FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands, regardless of the prescription channel [1]. Because KPV's eligibility is under evaluation rather than settled, that caveat is the operative one here [1][3].
This page is general information about the regulatory landscape. It is not medical or legal advice, and it is not an offer to sell or supply any substance.
Common questions about KPV legal status and access
Three questions come up repeatedly about where KPV stands. The short answers are below; each is drawn from the FDA framework described above.